Technology relates to an antibody against phosphorylated Ser-125-NPM1, its production method and use of highly specific antibodies against phosphorylated NPM1. NPM1 is identified as a novel substrate for Aurora kinases A and B, both acting on same site, Ser125 on NPM1 for phosphorylation during the onset of mitosis. Technology also discloses a method and kit used for production and usage of polyclonal antibodies specifically targeting Ser125 phosphorylated NPM1 along with pharmaceutically acceptable carrier could be used in diagnosis of tumor.

For more details about technology: Click here

Technology relates to a composition and a method of preparation of composition comprising substrate, semiochemical and an anti-oxidant, optionally along with additive. Invention also relates to a device or a trap comprising the composition. The composition results in controlled release of semiochemicals. The composition helps in protection of plants from pests.

Technology relates to a method of self-assembling naphthalene diimide derivatives, the proposed technology discloses the self-assembled nano, meso or micro structure of naphthalene diimide derivative with phenyl alanine, tryptophan, methyl ester of tryptophan or phenylalanine, and peptide containing tryptophan or phenyl alanine or methyl ester of phenylalanine or tryptophan as imide side chain. The proposed technology got wide range of applications in Biological, biomedical, supramolecular, and anticancer agents.

For more details about technology: Click here

Technology relates to a novel liposome formulation for delivery of anticancer agents such as Docetaxel (DTX) with significantly higher antitumor efficacy, preparation is simple and easy to scale up. The present formulation significantly improves the biopharmaceutics of difficult-to-deliver drugs such as DTX. About 10-15-fold and 20-25 fold increase in the circulation half-life and mean residence time was observed upon incorporation of DTX in TPGS-Liposomes, as compared to Taxotere.

For more details about technology: Click here

Invention relates to a novel nutraceutical products isolated and characterized from Moringa oleifera. The process involves the cold extraction of moringa seeds, which gives five different nutraceutical ingredients. This invention describes the nutraceutical and pharmaceutical activity of the products which have been isolated by a series of extraction techniques. One of the products extracted in such process is a complex characterized to be a type of glucosinolate combined with cationic protein, which is found to be very active against diabetes. The other product extracted can be used for wound healing.

Invention relates to an efficient, economical and industrially viable process for the preparation of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene (Retigabine). The process replaces genotoxic and potentially hazardous hydrazine hydrate as a deprotecting agent by new set of deprotecting agents . This technology also relates to the preparation processes of Retigabine intermediates.

For more details about technology: Click here